Literature DB >> 16809768

Prostate-specific membrane antigen regulates angiogenesis by modulating integrin signal transduction.

Rebecca E Conway1, Nenad Petrovic, Zhong Li, Warren Heston, Dianqing Wu, Linda H Shapiro.   

Abstract

The transmembrane peptidase prostate-specific membrane antigen (PSMA) is universally upregulated in the vasculature of solid tumors, but its functional role in tumor angiogenesis has not been investigated. Here we show that angiogenesis is severely impaired in PSMA-null animals and that this angiogenic defect occurs at the level of endothelial cell invasion through the extracellular matrix barrier. Because proteolytic degradation of the extracellular matrix is a critical component of endothelial invasion in angiogenesis, it is logical to assume that PSMA participates in matrix degradation. However, we demonstrate a novel and more complex role for PSMA in angiogenesis, where it is a principal component of a regulatory loop that is tightly modulating laminin-specific integrin signaling and GTPase-dependent, p21-activated kinase 1 (PAK-1) activity. We show that PSMA inhibition, knockdown, or deficiency decreases endothelial cell invasion in vitro via integrin and PAK, thus abrogating angiogenesis. Interestingly, the neutralization of beta(1) or the inactivation of PAK increases PSMA activity, suggesting that they negatively regulate PSMA. This negative regulation is mediated by the cytoskeleton as the disruption of interactions between the PSMA cytoplasmic tail and the anchor protein filamin A decreases PSMA activity, integrin function, and PAK activation. Finally, the inhibition of PAK activation enhances the PSMA/filamin A interaction and, thus, boosts PSMA activity. These data imply that PSMA participates in an autoregulatory loop, wherein active PSMA facilitates integrin signaling and PAK activation, leading to both productive invasion and downregulation of integrin beta(1) signaling via reduced PSMA activity. Therefore, we have identified a novel role for PSMA as a true molecular interface, integrating both extracellular and intracellular signals during angiogenesis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16809768      PMCID: PMC1592718          DOI: 10.1128/MCB.00084-06

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  80 in total

Review 1.  Biology of the p21-activated kinases.

Authors:  Gary M Bokoch
Journal:  Annu Rev Biochem       Date:  2003-03-27       Impact factor: 23.643

Review 2.  Cell migration: integrating signals from front to back.

Authors:  Anne J Ridley; Martin A Schwartz; Keith Burridge; Richard A Firtel; Mark H Ginsberg; Gary Borisy; J Thomas Parsons; Alan Rick Horwitz
Journal:  Science       Date:  2003-12-05       Impact factor: 47.728

Review 3.  Integrin activation.

Authors:  David A Calderwood
Journal:  J Cell Sci       Date:  2004-02-15       Impact factor: 5.285

4.  RhoA and ROCK promote migration by limiting membrane protrusions.

Authors:  Rebecca A Worthylake; Keith Burridge
Journal:  J Biol Chem       Date:  2003-02-06       Impact factor: 5.157

Review 5.  Angiotensin-I-converting enzyme inhibitors may be an alternative anti-angiogenic strategy in the treatment of liver fibrosis and hepatocellular carcinoma. Possible role of vascular endothelial growth factor.

Authors:  Hitoshi Yoshiji; Shigeki Kuriyama; Hiroshi Fukui
Journal:  Tumour Biol       Date:  2002 Nov-Dec

6.  CD13/APN transcription is induced by RAS/MAPK-mediated phosphorylation of Ets-2 in activated endothelial cells.

Authors:  Nenad Petrovic; Shripad V Bhagwat; William J Ratzan; Michael C Ostrowski; Linda H Shapiro
Journal:  J Biol Chem       Date:  2003-09-24       Impact factor: 5.157

Review 7.  Transmembrane proteases in cell growth and invasion: new contributors to angiogenesis?

Authors:  Brigitte Bauvois
Journal:  Oncogene       Date:  2004-01-15       Impact factor: 9.867

8.  Directional sensing requires G beta gamma-mediated PAK1 and PIX alpha-dependent activation of Cdc42.

Authors:  Zhong Li; Michael Hannigan; Zhicheng Mo; Bo Liu; Wei Lu; Yue Wu; Alan V Smrcka; Guanqing Wu; Lin Li; Mingyao Liu; Chi-Kuang Huang; Dianqing Wu
Journal:  Cell       Date:  2003-07-25       Impact factor: 41.582

9.  Prostate-specific membrane antigen association with filamin A modulates its internalization and NAALADase activity.

Authors:  Gopalakrishnapillai Anilkumar; Sigrid A Rajasekaran; Song Wang; Oliver Hankinson; Neil H Bander; Ayyappan K Rajasekaran
Journal:  Cancer Res       Date:  2003-05-15       Impact factor: 12.701

10.  Directional motility induced by epidermal growth factor requires Cdc42.

Authors:  Jeffrey Chou; Nancy A Burke; Akihiro Iwabu; Simon C Watkins; Alan Wells
Journal:  Exp Cell Res       Date:  2003-07-01       Impact factor: 3.905

View more
  75 in total

1.  Systematic discovery of nonobvious human disease models through orthologous phenotypes.

Authors:  Kriston L McGary; Tae Joo Park; John O Woods; Hye Ji Cha; John B Wallingford; Edward M Marcotte
Journal:  Proc Natl Acad Sci U S A       Date:  2010-03-22       Impact factor: 11.205

Review 2.  GCPII imaging and cancer.

Authors:  C A Foss; R C Mease; S Y Cho; H J Kim; M G Pomper
Journal:  Curr Med Chem       Date:  2012       Impact factor: 4.530

Review 3.  Opposing roles of folate in prostate cancer.

Authors:  Kevin J Rycyna; Dean J Bacich; Denise S O'Keefe
Journal:  Urology       Date:  2013-08-28       Impact factor: 2.649

4.  Imaging and Characterization of Macrophage Distribution in Mouse Models of Human Prostate Cancer.

Authors:  Ben T Copeland; Hassan Shallal; Chentian Shen; Kenneth J Pienta; Catherine A Foss; Martin G Pomper
Journal:  Mol Imaging Biol       Date:  2019-12       Impact factor: 3.488

5.  A theranostic "SMART" aptamer for targeted therapy of prostate cancer.

Authors:  Vittorio de Franciscis
Journal:  Mol Ther       Date:  2014-11       Impact factor: 11.454

6.  Prostate-specific membrane antigen (PSMA) expression in breast cancer and its metastases.

Authors:  Mariz Kasoha; Clara Unger; Erich-Franz Solomayer; Rainer M Bohle; Claudia Zaharia; Fadi Khreich; Stefan Wagenpfeil; Ingolf Juhasz-Böss
Journal:  Clin Exp Metastasis       Date:  2018-02-10       Impact factor: 5.150

Review 7.  Glutamate carboxypeptidase II in diagnosis and treatment of neurologic disorders and prostate cancer.

Authors:  C Bařinka; C Rojas; B Slusher; M Pomper
Journal:  Curr Med Chem       Date:  2012       Impact factor: 4.530

Review 8.  Looking for Drugs in All the Wrong Places: Use of GCPII Inhibitors Outside the Brain.

Authors:  James J Vornov; Diane Peters; Mike Nedelcovych; Kristen Hollinger; Rana Rais; Barbara S Slusher
Journal:  Neurochem Res       Date:  2019-11-20       Impact factor: 3.996

9.  Prostate-targeted mTOR-shRNA inhibit prostate cancer cell growth in human tumor xenografts.

Authors:  Yue-Feng Du; Qing-Zhi Long; Ying Shi; Xiao-Gang Liu; Xu-Dong Li; Jin Zeng; Yong-Guang Gong; Xin-Yang Wang; Da-Lin He
Journal:  Int J Clin Exp Med       Date:  2013-01-26

Review 10.  The therapeutic and diagnostic potential of the prostate specific membrane antigen/glutamate carboxypeptidase II (PSMA/GCPII) in cancer and neurological disease.

Authors:  James C Evans; Meenakshi Malhotra; John F Cryan; Caitriona M O'Driscoll
Journal:  Br J Pharmacol       Date:  2016-09-23       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.